|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 331.44 EGP | -20.00% |
|
+65.89% | +420.72% |
| 05-17 | GlaxoSmithKline Q1 consol net profit EGP 4.7 million | RE |
| 03-12 | GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Company Valuation: GlaxoSmithKline S.A.E
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,416 | 2,579 | 3,187 | 2,969 | 3,007 | 5,316 |
| Change | - | 82.08% | 23.58% | -6.84% | 1.27% | 76.81% |
| Enterprise Value (EV) 1 | 1,540 | 2,685 | 2,671 | 2,237 | 3,051 | 4,918 |
| Change | - | 74.37% | -0.55% | -16.25% | 36.39% | 61.21% |
| P/E | 50.4x | 16.7x | 4.33x | 49.1x | 17.3x | 24.9x |
| PBR | 1.17x | 1.9x | 1.84x | 1.51x | 1.51x | 2.4x |
| PEG | - | 0x | 0x | -0.5x | 0x | 1.1x |
| Capitalization / Revenue | 0.71x | 1.42x | 1.75x | 1.33x | 1.01x | 1.42x |
| EV / Revenue | 0.77x | 1.48x | 1.46x | 1x | 1.02x | 1.32x |
| EV / EBITDA | 6.67x | 9.65x | 55x | 4.7x | 6.55x | 18.5x |
| EV / EBIT | 7.6x | 11.1x | 174x | 5.07x | 7.16x | 22.7x |
| EV / FCF | 16.1x | 54.1x | 24.6x | 12.8x | -5.83x | 15.4x |
| FCF Yield | 6.22% | 1.85% | 4.06% | 7.79% | -17.1% | 6.5% |
| Dividend per Share 2 | - | 0.75 | - | 0.75 | - | 1 |
| Rate of return | - | 2.43% | - | 2.11% | - | 1.57% |
| EPS 2 | 0.3368 | 1.852 | 8.805 | 0.7239 | 2.083 | 2.553 |
| Distribution rate | - | 40.5% | - | 104% | - | 39.2% |
| Net sales 1 | 1,993 | 1,812 | 1,823 | 2,240 | 2,991 | 3,731 |
| EBITDA 1 | 230.9 | 278.3 | 48.6 | 475.6 | 465.8 | 265.1 |
| EBIT 1 | 202.5 | 242.2 | 15.33 | 441.5 | 425.9 | 216.6 |
| Net income 1 | 28.13 | 154.6 | 735.4 | 60.46 | 174 | 213.2 |
| Net Debt 1 | 123.6 | 106.4 | -516.3 | -732.3 | 44.01 | -397.9 |
| Reference price 2 | 16.96 | 30.88 | 38.16 | 35.55 | 36.00 | 63.65 |
| Nbr of stocks (in thousands) | 83,514 | 83,514 | 83,514 | 83,514 | 83,514 | 83,514 |
| Announcement Date | 5/30/22 | 5/30/22 | 3/18/24 | 3/18/24 | 3/9/25 | 3/12/26 |
1EGP in Million2EGP
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 690M | |
| 34.02x | 11.84x | 24.88x | 0.61% | 995B | |
| 28.36x | 6.26x | 17.51x | 2.11% | 614B | |
| 31.72x | 7.19x | 14.9x | 2.84% | 431B | |
| 19.93x | 4.73x | 11.72x | 2.79% | 353B | |
| 21.85x | 5.66x | 14.11x | 2.84% | 293B | |
| 20.2x | 4.19x | 11.86x | 2.11% | 245B | |
| 25.61x | 6.68x | 11.78x | 2.59% | 210B | |
| 13.52x | 5.15x | 10.43x | 3.7% | 210B | |
| -48.74x | 5.83x | 32.22x | 2.44% | 168B | |
| Average | 16.28x | 6.39x | 16.60x | 2.45% | 351.89B | |
| Weighted average by Cap. | 23.69x | 7.54x | 17.96x | 2.04% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- BIOC Stock
- Valuation GlaxoSmithKline S.A.E
Select your edition
All financial news and data tailored to specific country editions
